

Vatex
Vatex is developing a hybrid medical device-IT system to combat the abuse and trafficking of prescription drugs- a healthcare epidemic.
- Stage Product In Development
- Industry Healthcare Services
- Location Grapevine, TX, USA
- Currency USD
- Founded November 2010
- Employees 2
- Website divert-x.com
Company Summary
Vatex was formed to address the problem of prescription medication abuse. Vatex is developing Divert-X to monitor adherence to regimens for Controlled Substances. Patient compliance or behaviors consistent with abuse and trafficking will be established from real-time data of access to individual drug doses. Prescription drug misuse imposes a >$150 billion economic burden on US insurers- our customers. We will save lives and reduce costs.
Team
-
Simon SellersCEO
Simon Sellers, PhD, MBA is the Vatex CEO. Simon has thirty years of experience in the chemical and biotech industries in both mid-size companies and start-ups. His expertise includes business strategy, new product introductions and corporate development.
-
James HarrisCSO
James Harris, PhD is the inventor of the concept being developed by Vatex. He is a former FDA staffer and the founder of a biopharmaceutical start-up. He is an expert in applying modern automated instrumentation methods to medical analysis. Jim has broad interests in seeking solutions to major healthcare challenges. Jim and Simon were both principals at Bioavailability Systems, LLC - a drug development start-up company.
Previous Investors
-
Funded by managementUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.